Cingulate

Cingulate Inc. is a biopharmaceutical firm in the clinical development stage, dedicated to pioneering therapies for central nervous system and neurobiological conditions. Its leading investigational medicines are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), both designed to manage attention deficit/hyperactivity disorders (ADHD). Furthermore, the company is progressing CTx-2103 for the treatment of anxiety disorders. Established in 2012, Cingulate Inc. maintains its main office in Kansas City, Kansas, and also operates a facility in Morristown, New Jersey.